Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington Disease

  • STATUS
    Recruiting
  • End date
    May 22, 2026
  • participants needed
    26
  • sponsor
    UniQure Biopharma B.V.
Updated on 22 September 2021
chorea
htt gene

Summary

This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC). CT-AMT-130-01 is a Phase I/II, randomized, multicenter, dose escalation, double-blind, imitation surgery, first-in-human (FIH) study.

Description

AMT-130 is an investigational, single administration gene therapy intended to modify the disease course for HD. Preclinical studies have shown that AMT-130 lowers huntingtin protein and is associated with decreased progression of Huntington disease signs in animal models.

This 5-year trial consists of a blinded 12-month Core Study Period to evaluate the safety and potential impact of AMT-130 on disease progression and an unblinded 4-year Long-Term Period with periodic follow-up visits to evaluate the safety of AMT-130 and disease progression in treated individuals. Following completion of the 12-month blinded post treatment follow-up period, subjects will be individually unblinded. Once the crossover has been activated after review of data by the DSMB and FDA, subjects randomized to the imitation (sham) procedure who continue to meet inclusion/exclusion criteria (including adequate MRI striatal volumes) will be allowed to crossover to receive AMT-130 treatment.

Details
Condition Dementia, Huntington's Chorea, Huntington's Disease
Treatment rAAV5-miHTT, Imitation surgery, intra-striatal rAAV5-miHTT, Imitation (sham) surgery
Clinical Study IdentifierNCT04120493
SponsorUniQure Biopharma B.V.
Last Modified on22 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Early manifest HD as defined by a UHDRS total functional capacity (TFC) score of 9 to 13 and EITHER a diagnostic classification level (DCL) of 4 OR a DCL of 3 if the subject either meets the definition of multidimensional manifest HD (UHDRS question 80) or has cognitive symptoms
HTT gene expansion testing with the presence of 40 CAG repeats
Striatal MRI volume requirements per hemisphere: Putamen 2.5 cm3 (per side); Caudate 2.0 cm3 (per side)
All HD concomitant medications (addressing motor, behavioral, and cognitive symptoms) stable for 3 months prior to Screening
Able and willing to provide written informed consent
Able and willing to comply with all procedures and study visits

Exclusion Criteria

Evidence of suicide risk
Receipt of an experimental agent within 60 days or five half-lives prior to Screening or anytime over the duration of this study
Participation in an investigational trial or investigational paradigm (such as exercise/physical activity, cognitive therapy, brain stimulation, etc.) within 60 days prior to Screening or anytime over the duration of this study
Presence of an implanted deep brain stimulation device, ventriculoperitoneal or other CSF shunt, or other implanted catheter
Any history of gene therapy, RNA or DNA targeted HD specific investigational agents, such as antisense oligonucleotides (ASO), cell transplantation or any other experimental brain surgery
Any contraindication to lumbar puncture or 3.0 Tesla MRI as per local guidelines
Brain and spinal pathology that may interfere with the surgical delivery of AMT-130 or represents a significant neurologic comorbid disorder
Hospitalization for any major medical or surgical procedure involving general anesthesia within 12 weeks of Screening or planned during the study
Current or recurrent disease, infection, or other significant concurrent medical condition or medications that could confound clinical and laboratory evaluations or could affect a subject's safety or their ability to undergo the neurosurgical procedure or comply with the procedures and study visit schedule
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note